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OBJECTIVES: Currently the Australian government funds uni-
versal inﬂuenza vaccination for persons aged 65 years and over,
with annual vaccine coverage estimated to be 79%. However
over a quarter of Australians aged 50–64 years have an under-
lying medical condition which puts them at risk of severe conse-
quences from inﬂuenza, with annual vaccination rates of only
33% (government-subsidised and private) estimated for this age-
group. The objective of this study was to examine the cost-
effectiveness of extending universal free vaccination in Australia
to those aged 50–64 years. METHODS: A decision analytic
model previously developed for Europe was adapted to the
Australian setting. Costs and beneﬁts of universal inﬂuenza
vaccination were compared to those of the existing delivery
mechanisms in 50–64 year-olds. The following complications
were included: inﬂuenza-like illness, inﬂuenza-attributable hos-
pitalisations, inﬂuenza-attributable mortality, and work days
lost. The model distinguished between those at high-risk and
those at low-risk, to allow for different complication rates and
different vaccine uptake between risk groups. Rates of compli-
cations and their associated costs (A$, 2005) were based on
Australian-derived data, and vaccine effectiveness based on pub-
lished data. The discount rate was 5% consistent with Australian
policy. Cost-effectiveness ratios assessed included cost per Life-
Years Saved (LYS) and cost per Quality-Adjusted Life-Years
Saved (QALYS), and primarily considered the health care cost
perspective which is relevant to government funding decisions.
RESULTS: Compared to existing mechanisms, from a health care
perspective a universal inﬂuenza vaccination policy has an incre-
mental cost-effectiveness ratio (ICER) of A$9,660 per LYS, and
A$12,520 per QALYS. The most inﬂuential parameters in sensi-
tivity analysis included probability of death from inﬂuenza,
vaccine efﬁcacy against mortality, vaccine uptake, vaccine cost,
and cost of vaccine administration, although the upper values
were all below A$37,000. CONCLUSION: Universal inﬂuenza
vaccination of Australians aged 50–64 years is a highly cost-
effective strategy. The ICER is well within accepted thresholds for
government funding.
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OBJECTIVES: The study was aimed to 1) compare the costs of
different antibiotic regimens in the treatment of patients diag-
nosed with pneumonia that required hospitalization, and (2)
investigate if the initial choice of antibiotic affected the initial
treatment success rates and death rates. METHODS: The study
adopted a multi-center, retrospective case notes review design.
Patients aged above 18 years old admitted to the Princess Mar-
garet Hospital of Hong Kong during May 2005 to April 2006
and with a principal discharge diagnosis of pneumonia were
included. Direct medical costs were estimated based on the medi-
cations, diagnostic tests, hospital stay and allied-health profes-
sional visits. The study was conducted from a public hospital’s
perspective. RESULTS: A total of 333 medical case notes were
reviewed. The most commonly prescribed antibiotic regimen was
amoxycillin-clavulanate (AC) regimen (63.7%) as compared
to amoxycillian-clavulanate plus macrolide (ACM) regimen
(17.4%), quinolone (Q) regimen (8.4%) and others (10.5%).
The mean costs per patient for AC, ACM, and Q regimens were
US $ 6992 (SEM: 353.4), US $ 6856.0 (SEM: 496.1) and US
$ 6568.8 (SEM: 770.1) respectively. The treatment success rates
for AC, ACM and Q were 66.0%, 77.6% and 78.6% respec-
tively and the death rates were 13.7%, 0% and 14.3% respec-
tively. The mean costs per patient for AC, ACM and Q regimens
for patients with a history of chronic obstructive pulmonary
disease (COPD) were US $ 8778.2 (SEM: 727.9), US $ 9762.7
(SEM: 1476.4) and US $ 6712.0 (SEM: 1216.9) respectively.
CONCLUSION: There was no signiﬁcant cost difference in the
antibiotic regimens for pneumonia management. However, Q
regimen was found to be superior to AC and ACM regimens in
treating patients with COPD. Further studies involving more
patients and study sites are needed to conﬁrm the results.
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OBJECTIVES: Consistent with recommendations from profes-
sional societies, two of the most common approaches to empiric
community-acquired pneumonia (CAP) therapy are sequential
therapy with IV azithromycin plus IV ceftriaxone followed by
oral azithromycin, and IV levoﬂoxacin followed by oral levof-
loxacin. The purpose of this study is to asses the economic
impact of those regimens in a Spanish setting using an economic
model. METHODS: A cost-minimization analysis was per-
formed from the hospital perspective as the same efﬁcacy was
observed. Resource use was based on the results from a random-
ized, open-label multicenter trial (Zervos. Treat Respir Med
2004). Mean length of stay (LOS) and general medical wards
LOS were 8.8 and 7.4 days in the levoﬂoxacin group vs. 7.0 and
5.7 days in the azithromycin group. Days on study medication
was 13.7 IV + 2.9 oral and 3.2 IV + 12.2 oral in the levoﬂoxacin
and azithromycin group, respectively. Only in-hospital (€2007)
direct costs per-patient were considered: hospitalization costs
(ICU-general ward), drug acquisition cost (at their hospital
selling prices) and administration costs. Costs were obtained
from Spanish databases. Univariate and bivariate threshold sen-
sitivity analyses were carried out to test the robustness of the
model. RESULTS: Mean cost per patient treated is estimated to
be €2666.0 with azithromycin plus ceftriaxone and €3532.9 with
levoﬂoxacin, with an incremental cost of €866.9. Azithromycin-
LOS reduction was the main cause for most of the difference cost.
The sensitivity analysis showed that levoﬂoxacin would be less
costly than azithromycin only if levoﬂoxacin-LOS were lower
than 4.8 days. The robustness of the model is related to daily cost
and LOS. CONCLUSION: According to this model, azithromy-
cin plus ceftriaxone is less costly than levoﬂoxacin-monotherapy
for treating community-acquired pneumonia patients requiring
hospitalization in Spain. The cost beneﬁt attributable to azithro-
mycin depends on its role in reducing the length of stay.
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